GWM
ACAD icon

Gilpin Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Gilpin Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$383 Hold
19
– – ﹤0.01% 933
2026
Q2 		$481 Buy
19
+6
+46% +$132 ﹤0.01% 686
2026
Q1 		$290 Buy
13
+4
+44% +$96 ﹤0.01% 772
2025
Q4 		$241 Buy
+9
New +$215 ﹤0.01% 612

Other funds holding ACAD

GI
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's ACAD Position: Q3 2026 in Review

Gilpin Wealth Management held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 19 shares worth $383. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Gilpin Wealth Management first reported a position in ACAD in Q4 2025 and has held it in 4 quarters since. The position peaked at $481 in Q2 2026. 10 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Gilpin Wealth Management held 19 shares of Acadia Pharmaceuticals worth $383 as of Q3 2026.
  • Gilpin Wealth Management left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #933 holding.
  • Gilpin Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Acadia Pharmaceuticals position peaked at $481 in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.